|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2010-2-12
|
|
pubmed:abstractText |
Data on long-term efficacy of bosentan, an oral dual ET receptor antagonist, in SSc-associated pulmonary arterial hypertension (SSc-PAH) are lacking. We aimed to describe the long-term outcome of SSc-PAH treated with first-line monotherapy bosentan followed or not by the addition of prostanoids or sildenafil.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antihypertensive Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Epoprostenol,
http://linkedlifedata.com/resource/pubmed/chemical/Iloprost,
http://linkedlifedata.com/resource/pubmed/chemical/Piperazines,
http://linkedlifedata.com/resource/pubmed/chemical/Purines,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Endothelin A,
http://linkedlifedata.com/resource/pubmed/chemical/Sulfonamides,
http://linkedlifedata.com/resource/pubmed/chemical/Sulfones,
http://linkedlifedata.com/resource/pubmed/chemical/bosentan,
http://linkedlifedata.com/resource/pubmed/chemical/sildenafil
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1462-0332
|
|
pubmed:author |
pubmed-author:AchouhLaraL,
pubmed-author:HumbertMarcM,
pubmed-author:JaisXavierX,
pubmed-author:LaunayDavidD,
pubmed-author:Le PavecJérômeJ,
pubmed-author:ParentFlorenceF,
pubmed-author:SavaleLaurentL,
pubmed-author:SimonneauGéraldG,
pubmed-author:SitbonOlivierO,
pubmed-author:TchérakianColasC,
pubmed-author:YaïciAzzedineA
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
49
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
490-500
|
|
pubmed:meshHeading |
pubmed-meshheading:20015974-Adult,
pubmed-meshheading:20015974-Aged,
pubmed-meshheading:20015974-Antihypertensive Agents,
pubmed-meshheading:20015974-Drug Administration Schedule,
pubmed-meshheading:20015974-Drug Therapy, Combination,
pubmed-meshheading:20015974-Epidemiologic Methods,
pubmed-meshheading:20015974-Epoprostenol,
pubmed-meshheading:20015974-Exercise Test,
pubmed-meshheading:20015974-Female,
pubmed-meshheading:20015974-Hemodynamics,
pubmed-meshheading:20015974-Humans,
pubmed-meshheading:20015974-Hypertension, Pulmonary,
pubmed-meshheading:20015974-Iloprost,
pubmed-meshheading:20015974-Male,
pubmed-meshheading:20015974-Middle Aged,
pubmed-meshheading:20015974-Piperazines,
pubmed-meshheading:20015974-Purines,
pubmed-meshheading:20015974-Receptor, Endothelin A,
pubmed-meshheading:20015974-Scleroderma, Systemic,
pubmed-meshheading:20015974-Sulfonamides,
pubmed-meshheading:20015974-Sulfones,
pubmed-meshheading:20015974-Treatment Outcome
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil.
|
|
pubmed:affiliation |
Universite Paris-Sud, Faculte de Medecine, Kremlin-Bice tre, France.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|
